Form 4: 89bio Director Disposes Shares in Roche Merger

89bio, Inc. director Michael R. Hayden disposed of all his common stock and stock options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a contingent value right.

Summary

• Michael R. Hayden, a director of 89bio, Inc., reported the disposition of all his beneficial ownership in the company.
• This disposition occurred on October 30, 2025, following the completion of a merger where 89bio became a wholly-owned subsidiary of Roche Holdings, Inc.
• The merger involved a tender offer by Roche Holdings, Inc. for all outstanding shares of 89bio common stock.
• Shareholders received an offer price of $14.50 per share in cash, plus one non-tradeable contingent value right (CVR) potentially worth up to an additional $6.00 per share upon achievement of specified milestones.
• All outstanding stock options became fully vested and exercisable immediately prior to the merger.
• Options were either converted into cash and CVRs (if in-the-money) or CVRs only (if out-of-the-money but below $20.50 exercise price), or cancelled without payment (if exercise price was $20.50 or greater).

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a premium for their shares and potential upside via CVRs, representing a successful exit for 89bio as an independent entity. However, the non-tradeable nature of CVRs and the cancellation of high-strike options introduce some caveats.

Positives

• The merger provides a clear exit strategy and liquidity for 89bio shareholders.
• Shareholders received a guaranteed cash payment of $14.50 per share.
• The inclusion of a Contingent Value Right (CVR) offers potential upside of up to $6.00 per share based on future milestone achievements.
• All outstanding stock options held by the reporting person became fully vested and exercisable prior to the merger, allowing for their conversion into cash and/or CVRs.

Negatives

• 89bio, Inc. ceases to be an independent publicly traded company, removing future independent growth potential for existing shareholders.
• The CVRs are non-tradeable, limiting liquidity for the contingent portion of the consideration.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.

Risks

• The value of the CVRs is contingent on the achievement of specified milestones, meaning the full $6.00 per share is not guaranteed.
• Shareholders are now exposed to the performance of Roche Holdings, Inc. indirectly through the CVRs, rather than directly through 89bio's independent operations.
• The non-tradeable nature of CVRs means investors cannot sell them for immediate cash, and their ultimate value is uncertain until milestones are met or missed.

Future Outlook

89bio, Inc. is now a wholly-owned subsidiary of Roche Holdings, Inc., and its future operations will be integrated within Roche's structure. The future value for former 89bio shareholders holding CVRs depends entirely on the achievement of specific milestones related to 89bio's assets under Roche's ownership.

Industry Context

This acquisition reflects the ongoing consolidation and strategic M&A activity within the biotechnology and pharmaceutical sectors. Larger pharmaceutical companies like Roche often acquire smaller biotech firms with promising pipelines to bolster their own portfolios and drive future growth, especially in areas like metabolic diseases or other therapeutic indications 89bio might have been focused on.

Comparison to Industry Standards

• The acquisition price of $14.50 cash plus a CVR up to $6.00 per share (total potential $20.50) should be compared to recent biotech M&A transactions on a per-share or enterprise value basis.
• For example, similar acquisitions in the NASH or metabolic disease space (if that was 89bio's focus) would provide benchmarks for valuation multiples (e.g., revenue multiples, pipeline value, or premium to pre-announcement share price).
• The structure with a CVR is common in biotech acquisitions, allowing the acquirer to mitigate risk on unproven assets while providing upside for the target's shareholders if development milestones are met. This aligns with industry practices for valuing clinical-stage assets.

Related Party Transactions

• The reporting person's indirect ownership of 103,978 common shares through Genworks 2 Consulting Inc. and 61,538 common shares through The Hayden Family Trust, both over which his wife has sole voting and investment power, were disposed of as part of the merger.

Stakeholder Impact

• Shareholders: Received $14.50 cash per share plus a CVR potentially worth up to $6.00 per share, providing liquidity and potential upside.
• Employees: Likely integrated into Roche's structure, with potential changes in roles, benefits, or employment terms.
• Customers/Suppliers: Operations likely continue under Roche's ownership, potentially leading to changes in relationships or contracts over time.

Next Steps

• Former 89bio shareholders holding CVRs will await announcements regarding the achievement of specified milestones to realize potential additional payments.
• Roche Holdings, Inc. will proceed with the integration of 89bio's assets and operations.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Beneficial Ownership, Insider Trading, Form 4, Biotechnology, Pharmaceuticals